retatrutide clinical trials phase ESC 2024: improves lipid and cardiovascular risk profile in II trial Eli Lilly infiltrates anti-obesity market

Semaglutide is a breakthrough medication belonging to a class of drugs known as GLP-1 (Glucagon-Like Peptide-1) receptor agonists

Description Retatrutide is an advanced triple-agonist peptide developed by Eli Lilly that simultaneously activates the GLP-1, GIP, and glucagon receptors

Additional factors such as increased release of adiponectin from adipose tissue, amelioration of insulin resistance in liver and peripheral tissues, and improved circulatory lipid profile all contribute to the reduced risk of ASCVD (267)

Gut microbiota regulates maturation of the adult enteric nervous system via enteric serotonin networks